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Purpose: A validated disease severity scoring system (DS3) for Gau-
cher disease type 1 (GD1) is needed to standardize patient monitoring
and to define patient cohorts in clinical studies.Methods: DS3 domains
were established by an expert physician group using the nominal group
technique of consensus formation. Items were selected by 36 GD1
physicians. The expert group determined appropriate measurement
techniques for each item. Measurements were weighted considering
contributions to GD1 morbidity and mortality. Consensus Clinical
Global Impression Severity scores for sample cases were compared with
average DS3 scores. A minimal clinically important difference in GD1
DS3 score was calculated. Results: The GD1 DS3 includes bone (42%
of score), hematologic (32%), and visceral domains (26%); individual
items use routine assessments, including medical history, blood chem-
istry, organ volume measurements, and bone evaluations (magnetic
resonance imaging and dual x-ray absorptiometry). The maximum score
is 19. Interrater reliability was 0.97 (Cohen’s kappa). DS3 scores were
highly correlated with Clinical Global Impression Severity scores (r2 
0.89). The minimal clinically important difference was 3.2 improve-
ment and 3.9 deterioration. Conclusion: This DS3 accurately quan-
tifies GD1 status and intrapatient change over time. Testing of reliability
and validity will continue to allow eventual implementation of the DS3
in clinical studies and routine practice. Genet Med 2010:12(1):44–51.
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Gaucher disease (GD) is an autosomal-recessive inborn errorof glycosphingolipid metabolism caused by loss-of-func-
tion mutations in the gene encoding lysosomal glucocerebrosi-
dase (GCase; EC 3.2.1.45). When GCase activity is diminished,
glucosylceramide accumulates primarily in the lysosomes of
macrophages (“Gaucher cells”). GD is broadly subdivided into
neuronopathic (types 2 and 3) and non-neuronopathic (type 1)
phenotypes. GD type 1 (GD1, OMIM 230800), the most com-
mon variant with an estimated prevalence of between 1:40,000
and 1:60,000,1–3 is traditionally defined by the absence of pri-
mary central nervous system involvement. Worldwide, GD1
constitutes 95% of all cases,4 although the relative number of
patients with neuronopathic variants is often substantially
greater in Asian, Middle Eastern, and African populations. The
common clinical manifestations are hematological cytopenias,
hepatomegaly, splenomegaly, and various skeletal disorders.
Disease expression is diverse. Some individuals homozygous
for mutations in the glucocerebrosidase gene, especially those
of Ashkenazi Jewish origin, are asymptomatic or are only
mildly affected, at least until late in adulthood.4,5 However,
others, including Ashkenazi Jews, have more severe and poten-
tially disabling manifestations including irreversible bone disease
with osteolytic lesions, avascular necrosis and marked osteoporo-
sis.5,6 The rate and extent of disease progression are variable.
Treatment, most commonly with enzyme replacement therapy,
effectively ameliorates many of the manifestations of GD1.7–10
However, because genotype-phenotype correlations are im-
precise, it is difficult to predict who will benefit from expensive,
potentially life-long therapies and who may suffer if treatment
is withheld, interrupted, or otherwise modified. A validated,
reproducible, and broadly applicable tool to classify GD1 se-
verity at any stage of the disease would greatly facilitate clinical
studies that seek to identify predictive factors for prognosis or
define disease management criteria.
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Current severity scoring indices for GD, such as the Zimran
Severity Score Index (SSI)11 and Hermann score for bone dis-
ease,12 were conceived in the pretreatment era. These systems
include quantifiable parameters that can change over time or with
treatment (organ volumes, serum liver-related tests, subjective pain
assessments) but also assign substantial weight to constants (sple-
nectomy, osteonecrosis, imaging abnormalities) and thus may not
be sufficiently sensitive to define slowly responding therapeutic
changes.13 The Zimran SSI score has not been tested with contem-
porary methods to assess performance parameters nor has its re-
sponsiveness to intrapatient changes in disease manifestations over
time been established. As a result, the instrument has not been
widely used in routine clinical practice or as an endpoint in clinical
trials. More recently, an alternate SSI (GauSSI-I) has been pro-
posed for GD1.14 However, this scoring system has yet to be
validated and its routine use may be limited because of its com-
plexity and the technological requirements of some of the compo-
nent assessments. It may prove useful in limited applications such
as single-center clinical trials.
A disease severity scoring system (DS3) expresses an inte-
grated assessment of the burden of disease in a given patient.
Ideally, the DS3 could be used to assess patient status, deter-
mine endpoints in clinical studies, classify disease subgroups,
and compare outcomes among patients with similar levels of
disease severity. DS3s use a minimal data set to score the
patient in a comprehensive manner using groups of domains
(often by organ system) that are populated with nonredundant
items. Items should be valid and reliable, use feasible, standard-
ized methods of assessment, and be weighted based on associ-
ated morbidity and mortality. A validated DS3 for GD1 is
needed to guide clinicians as to when GD-specific therapy
should be started, to monitor disease progression and treatment
response in individuals, and to compare patient cohorts in
clinical studies. Such disease severity scoring systems have
already been developed for other chronic diseases such as
rheumatoid arthritis.15,16 Here, we describe the development of
a DS3 for adult GD1 patients as well as testing of the instrument
for validity (content, face, criterion, discriminant, and construct
validity), reliability, and feasibility.
MATERIALS AND METHODS
Instrument development
Domain selection
Recognized experts in GD1 were invited to participate and a
DS3 Working Group comprised of nine GD1 experts from across
the globe, representing multiple medical specialties, was formed; a
methodologist-biostatistician experienced in the development of
instruments for outcomes measurement was engaged to facilitate
construction and validation of the GD1-DS3. A consensus confer-
ence was held in December 2006 to initiate development of the
instrument. Putative domains were identified using the nominal
group technique (NGT) of consensus formation.17
Domains and items
Seventy-four international non-Working Group physicians
with experience in GD were invited in an electronic survey to
propose quantifiable items for each domain that they considered
“most relevant to the assessment and quantitative measurement
of the activity/severity of Gaucher disease.” They were also
asked to rank the proposed domains in order of importance and
to propose additional domains. The Working Group then used
NGT to determine whether any domains originally proposed
should be eliminated or whether new domains should be in-
cluded. Items proposed were evaluated in terms of reliability,
feasibility, and validity; duplicative or unnecessary items were
eliminated. The methods of assessment appropriate for each
item were selected by the Working Group using NGT consen-
sus. A preliminary weighting system for items and domains was
arrived at by NGT.
Validation and optimization
Content, face, criterion, discriminant, and construct validity
were evaluated at two face-to-face conferences attended by 12
international experts in GD with no prior exposure to the DS3
(Table 1).18 Validation conference participation and logistics
were arranged to coincide with major US and European Gau-
cher-related medical congresses. Deidentified patient profiles
(n  20) were suggested by Working Group members and were
obtained from the International Collaborative Gaucher Group
Gaucher Registry. Each patient profile contained complete clin-
ical and diagnostic information from two sequential clinic visits,
an initial and a follow-up visit, and was selected regardless of
treatment status (all patients were untreated at the time of the
initial visit). No values were imputed. Twenty profiles were
chosen to achieve a reasonable assessment of sensitivity and
specificity while limiting the time investment involved in scor-
ing. Patient profiles were scored using the Clinical Global
Impression (CGI) scale, which is used in a variety of other
disease states.19–21 Each profile was scored for each visit for the
overall extent of disease severity summarized as the CGI-
Severity (CGI-S) score. The degree of change between visits
was characterized using a CGI-Improvement score to rate each
patient’s status at the follow-up visit as “improved,” “not
changed,” or “worsened” from the initial visit. Participants were
also asked to determine whether the change in the patient’s
status would trigger a change in treatment or prognosis. NGT
was used to achieve consensus on CGI scores and therapy/
prognosis change. Participants then individually scored the pa-
tient profile for each visit using the DS3. Results from the two
individual conferences were not substantially or statistically
different and were combined for analyses.
Participants also rated the feasibility and content validity of
the DS3 using a validated technique that uses a 4-point scale,
where 1 represented the worst feasibility/content validity and 4
represented the best feasibility/content.22 Additional feasibility
and content validity testing was later carried out when an
additional group of 23 physicians attending a GD workshop
reviewed the DS3, scored a sample case, and rated the DS3 for
feasibility and content validity using the same scale used at the
validation conferences. Results from all 35 ratings were used to
generate Feasibility Index and Content Validity Index scores
(see Statistical Methods section).
An additional correlation exercise compared CGI-S scores
with that of the Zimran SSI.11 The original Working Group
scored the 20 GD1 patient profiles for the initial and the fol-
low-up visits using the Zimran SSI. For each patient, Zimran
SSI scores were compared with the CGI-S scores obtained at the
second validation conference.
Inclusion of items was refined according to statistical testing
of reliability and stability. Additionally, scaling of and maxi-
mum scores for individual assessments within the DS3 were
optimized to maximize the correlation between the total scores
of the instrument and the consensus CGI-S scores using Excel
2002 Solver; this tool uses the Generalized Reduced Gradient-2
algorithm for optimizing nonlinear problems. The DS3 was
optimized to maximize correlation with the CGI-S under con-
ditions where bone density and infiltration data (the items
judged most likely to be missing) were either present or absent.
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Determination of the minimal clinically important
difference
Minimal clinically important difference (MCID) represents
the amount of change, either increase or decrease, in the instru-
ment score that would usually indicate a change in some aspect
of the disease or trigger an adjustment in medical care or
prognosis. It is not synonymous with a difference that is statis-
tically significant. We estimated MCID for the DS3 using data
from the validation conference. Physicians were asked whether
they felt that the observed change from one visit to the next
would worsen, not change, or improve the patient’s prognosis.
Using CGI, the physicians came to a consensus decision regard-
ing these two standards for each of the 20 sample patient
profiles, given the change in the DS3. MCID was calculated as
the amount of change in the DS3 score at which at least 75% of
the physicians agree that there would be a change in progno-
sis.23 MCID for worsening was the change in the DS3 score at
which at least 75% of physicians agreed that the patient’s
prognosis had worsened, and MCID for improvement was the
change in the DS3 score at which at least 75% of physicians
agreed that the patient’s prognosis had improved.
Statistical methods
The Pearson rank coefficient was used to determine the
correlation between the SSI and the DS3 scores. Each patient
profile included data from an initial and follow-up visit, and
each visit was scored using both the SSI and DS3. To increase
the precision of the estimate of Pearson’s rank coefficient (R),
data from both the initial and follow-up visits were used in the
calculation. Interrater reliability of the optimized DS3 instru-
ment was assessed by having two independent raters score 10 of
the patient profiles, and the level of agreement was estimated
using Cohen’s kappa coefficient.
The Content Validity Index is the proportion of physicians
who scored the instrument as either 3 (relevant but needs minor
alterations) or 4 (very relevant and succinct). The Feasibility
Index was calculated in the same manner as the Content Valid-
ity Index, with a score of 3 equal to feasible but needs minor
alterations and a score of 4 equal to very feasible. A value of 0.8
or greater indicates that at least 80% of respondents find the
instrument acceptable with respect to the quality assessed.
RESULTS
Instrument development
Domain and item selection
Six domains were initially selected for inclusion in the DS3:
bone disease/skeletal, growth/metabolism, hematological, vis-
ceral, patient reported, and physician reported. Thirty-six of 74
(49%) respondents from around the world completed the elec-
tronic survey. Table 2 shows the relative importance of each
domain as ranked by the survey respondents.
The three lowest-rated domains (patient reported, physician
reported, and growth/metabolism) were eliminated. Patient-re-
ported pain was integrated into the bone domain. The primary
impact on the health-related quality of life in patients with GD1
is pain.23 Including the pain component in the bone domain
captures this dimension with less risk of redundancy. Fatigue,
another patient-reported item, was considered by the Working
Group to be a symptom often associated with other disease
manifestations (e.g., anemia) and was therefore not incorpo-
rated. The growth/metabolism domain was eliminated, because
Table 1 Commonly used criteria for evaluating disease scoring systems18
Feasibility Easily performed in the routine clinic
Inexpensive and quick
Low risk to the patient
Reliability (reproducibility) Of methods of assessments of each variable
Intra- and inter- rater
Of the instrument overall (internal consistency/reliability)
Validity Face Clinical sensibility to the end-user
Content Both consensus and quantitative
Criteria must consider all relevant aspects of disease that contribute to morbidity,
without the inclusion of redundant items
Criterion Agreement with a gold standard criterion
Sensitivity, specificity, and area under the curve
Predictive validity
Discriminant Ability to pick up smallest amount of change considered to be the minimal clinically
important difference (MCID)
Responsiveness to change over time
Construct Criteria do what they are designed to do
Convergent Results correlate with other tools that measure same construct
Divergent Results do not correlate with tools that measure different constructs
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it applies primarily to children and adolescents, whereas this
instrument is designed solely for adult patients. Finally, the
physician-reported domain, including a physician’s global as-
sessment, was eliminated because in rare diseases in which
caregivers often see too few patients to develop clinical exper-
tise the physician’s global assessment may not be reliable. All
items in the hematologic domain (thrombocytopenia, bleeding,
anemia) were retained, because each is considered to be a
clinically significant, nonredundant manifestation of GD1.
Selection and weighting of item measurements
For each item, the Working Group evaluated all known
assessment options and selected methods of measurement based
on feasibility and availability of technology, with the intention
of containing costs and avoiding additional risks to patients.
Preliminary weighing of measurements arrived at by Working
Group consensus was assigned according to the extent that
morbidity and mortality in each measurement contributes to
Fig. 1. Gaucher Disease Type 1 Disease Severity Scoring System instrument.
Table 2 Importance of each domain, as ranked by 36 Gaucher disease physicians in the initial survey
Domain
Rank
Average rank1 2 3 4 5 6
Bone disease/skeletal 17 (53%) 4 (13%) 5 (16%) 1 (3%) 0 (0%) 5 (16%) 2.31
Growth/metabolism 3 (9%) 3 (9%) 5 (16%) 6 (19%) 12 (38%) 3 (9%) 2.76
Hematological 7 (21%) 13 (39%) 3 (9%) 4 (12%) 3 (9%) 3 (9%) 3.63
Patient-reported 2 (6%) 5 (16%) 8 (25%) 3 (9%) 7 (22%) 7 (22%) 3.77
Physician-reported 7 (23%) 3 (10%) 3 (10%) 5 (16%) 3 (10%) 10 (32%) 3.91
Visceral 0 (0%) 7 (20%) 9 (26%) 11 (31%) 6 (17%) 2 (6%) 3.94
Values indicate count and percentage of respondents selecting the option.
1  most important and 6  least important.
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GD1 severity. Weighing was optimized as described to obtain
the final working model of the GD1-DS3 (Fig. 1).
Working model and scoring method
The GD1-DS3 has three domains: bone, hematological, and
visceral. Each domain contains three or more items, each scored
individually by the evaluating physician. The domain score is
tabulated by averaging the scores for all items within the do-
main. A total GD-DS3 score is the sum of the three domain
scores, with a maximum score of 19 points. A scoring reference
guide was developed.
Validation
Feasibility and content validity
The Content Validity Index was 0.96, and the Feasibility
Index was 0.95.
Fig. 1. (Continued).
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Interrater and intrarater reliability
The intraclass correlation coefficient between any two
physicians in scoring 10 patients using the GD1-DS3 was
0.97 (Cohen’s kappa), indicating no significant difference
between raters and a high level of concordance. Assessment
of intrarater reliability, although initially planned, was not
carried out.
Correlation with existing scales (construct and
criterion validity)
Figure 2 represents the Pearson correlation of the GD1-DS3
with CGI-S scores from the validation conferences. In general,
patients with “mild” disease as assessed by the CGI-S had GD1-
DS3 scores3, “moderate” disease correlated with DS3 scores of
3 to 6, “marked” disease 6 to 9, and “severe” disease 9. Corre-
lation with the CGI-S was R2  0.89 when both bone density and
infiltration data were available. In the absence of these data points,
the correlation was R2  0.77.
Correlation between the CGI-S and the SSI was weak (R2 
0.51). The Pearson correlation between the SSI and the GD1-
DS3 was R2  0.60.
Minimal clinically important difference
The MCID for improvement in GD1-DS3 score was found to
be a decrease of 3.17 and for worsening was 3.86. Cases
scored as “no change in prognosis” by at least 75% of the
physicians had changes in GD1-DS3 score that fell between
these two values.
DISCUSSION
Methodological approaches for development of instruments
to assess severity and monitor disease progression in any dis-
ease are necessarily complex. Rare conditions with heteroge-
neous clinical presentations such as GD1 pose even greater
challenges. This study describes the development and validation
of a new disease severity scoring system for GD1 and compares
its outcomes with the only widely used GD1 severity score, the
Zimran SSI,11 which was developed before disease-specific
treatment for GD was available. Initial estimations of validity,
reliability, and theoretical feasibility suggest that it is a practi-
cable and reliable instrument for assessing disease severity and
progression.
The GD1-DS3 offers an advantage over simply monitoring
individual signs and symptoms of GD1. In a disease where
varying clinical manifestations may present irregularly and
progress at different rates even within the same patient, a
weighted global assessment is required to accurately portray
individual disease status. Besides providing a conspectus of
disease severity and progression, the structure of the GD1-DS3
corresponds well with published therapeutic goals for the treat-
ment of GD124 and may facilitate monitoring of these goals as
part of an integrated management approach to this chronic
disease. It improves upon the Zimran SSI by incorporating
modern methods for assessing bone marrow infiltration and
bone mineral density.
The GD1-DS3 is also potentially useful for reliable interpa-
tient comparisons. In diseases such as GD1 with no well-
Fig. 2. Correlations between the Clinical Global Impression Scale–Severity (CGI-S) and the Gaucher Disease Type 1
Disease Severity Scoring System (GD1-DS3) score for 20 patient profiles, each scored at two different time points by 12
Gaucher disease experts. CGI-S scores of 1–1.5 indicate “mild,” 1.5–2.0 “moderate,” 2.0–2.5 “marked,” and 2.5–3.0
“severe” disease. Boxes show that, for most patients at most time points, CGI-S scores in each half-point range correspond
with a 3-point range of GD1-DS3 scores.
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documented biomarker or singular symptom complex that ad-
equately captures disease severity, clinical trial endpoints are
often difficult to define. A validated scoring system with estab-
lished reliability and sensitivity can facilitate comparison of
trial groups and monitoring patient outcomes over time. It may
also serve as a quantitative means to facilitate health outcomes
research as well as epidemiological investigations.
Although the GD1-DS3 seems to perform well in those
parameters tested, additional refinement and continued valida-
tion are required. Further evaluation of performance character-
istics must be completed. For example, the comparison of the
GD1-DS3 with the CGI provided one measure of criterion
validity, which seems to be high. Additional evidence of crite-
rion validity will be provided as sensitivity, specificity, and area
under the curve are determined. Feasibility, although thought to
be high based on the validators’ assessments, also needs to be
proven in the clinic.
Prospective validation exercises are typically the final test of
the validity of an instrument. Such testing is currently being
planned for the GD1-DS3. Predictive validity has yet to be
determined. Construct validity has been partially demonstrated,
as the instrument was shown to correlate very well with the
CGI-S. Divergent validity, frequently ignored in validity test-
ing, should also be established; this can be accomplished using
the GD1-DS3 to assess patients with diseases with similar
symptom profiles, such as rheumatoid arthritis, and comparing
the scores with those obtained from patients with GD1.
This DS3 scoring system is unsuitable for use in pediatric
patients with GD1. This is a significant limitation because about
26% of the International Collaborative Gaucher Group Registry
population are currently younger than 18 years (Genzyme Cor-
poration, data on file) and new patients are increasingly diag-
nosed in childhood. The authors believe that a separate DS3 will
be necessary for pediatric patients, as disease domains that are
critical in pediatric GD are not relevant to adults (e.g., those
relating to growth and development). In its current form, the
tool is also inapplicable to patients with neuronopathic GD.
Finally, the GD1-DS3 is subject to confounding by concurrent
acquired illnesses.
Although the GD1-DS3 will provide clinicians with an im-
portant tool for assessing and monitoring adult patients with
GD1, its contextual interpretation is subject to the clinical
judgment of the treating physician. The GD1-DS3 may provide
a useful tool for evaluating a patient over time and in relation to
other patients, but it is not a substitute for careful and thorough
listening and observation. GD1-DS3 scores should not be ex-
pected alone to dictate treatment decisions such as initiation of
treatment or dosage adjustment, particularly because therapy
for GD1 is often intended to prevent development of symp-
toms as much as to treat existing symptoms. Clinical and
laboratory assessments other than those incorporated into
this instrument, as well as patient-reported outcomes, play a
critical role in the effective management of GD1. Individual
patients will have unique combinations of GD-related symp-
toms as well as comorbidities, emotional issues, and socio-
economic concerns that must be evaluated and dealt with on
a case-by-case basis.
The GD1-DS3 provides a reliable method of assessing both
intra- and interpatient severity of GD1 in adults. It is easy to
implement and requires no assessments beyond the normal
standard of care for such patients in the contemporary clinical
setting. Our results demonstrate that, in its current form, the
instrument is highly correlated with the clinical assessment of
physicians who are expert in this field. Furthermore, we have
shown that it is perceived as feasible and highly acceptable by
physicians of varying specialties and nationalities who care for
Gaucher patients. Definitive validation will require more exten-
sive retrospective studies and prospective studies in different
populations.
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